South & Central America Lung Cancer Screening Market Forecast to 2030 - Regional Analysis- by Cancer Type, Age Group, and End User

The South & Central America lung cancer screening market is expected to grow from US$ 39.16 million in 2022 to US$ 68.95 million by 2030. It is estimated to grow at a CAGR of 7.3% from 2022 to 2030.

High cost of lung cancer screening tests fuel South & Central America lung cancer screening market.

Amid growing healthcare awareness in the region, lung cancer screening providers in the region has ample opportunities. These include collaborating with regional hospitals and clinics through which they can offer accessible lung cancer screening and leveraging telemedicine for remote areas. This approach not only detects lung cancer early but also improves patient outcomes, filling a crucial gap in the region’s healthcare. By aligning with the rising demand for preventive care, these providers can establish a foothold in a promising market, ultimately contributing to enhanced public health and well-being across the region.

South & Central America Lung Cancer Screening Market Overview

The South & Central America lung cancer screening market is segmented into the Brazil, Argentina, and the Rest of South & Central America. The regional growth is attributed to various factors, such as the increasing incidence of lung cancer and growing awareness of lung cancer screening among people. Also, rising government support for screening has led to the further growth of the market.

The lung cancer screening market is being influenced by factors such as the increasing prevalence of cancer. For instance, as per Globocan 2020 report, lung cancer is Brazil's second most prevalent cancer. There were 88492 new cases of lung cancer found in Brazil.

Lung cancer screening is believed to be the standard of care worldwide. In Brazil, complications in its implementation related to the organization of the health system, access to CT scans and treatment methods, and cultural acceptance of the method restrict the process. There are challenges and barriers in carrying out the screening according to the local organization; however, it was possible to obtain satisfactory results in all scenarios.

According to Lung Cancer Policy Network, In Brazil, a coordinated approach to lung cancer screening is necessary, as health assistance is fragmented across the country and has resulted in significant health inequalities. The advantages of LDCT screening were recently described in the Second Brazilian Early Lung Cancer Screening Trial (BRELT2). Nevertheless, there are still many barriers to overcome before an organized screening program can be implemented nationwide, including inequitable access to screening equipment between public and private healthcare. To manage this challenge, as part of the Propulmão Mobile Project, the municipal health office in Barretos (São Paulo) collaborated with the local cancer hospital to deliver mobile LDCT screening and a smoking cessation intervention in the community.

South & Central America Lung Cancer Screening Market Revenue and Forecast to 2030 (US$ Million)

South & Central America Lung Cancer Screening Market Segmentation

The South & Central America lung cancer screening market is segmented into cancer type, technology, age group, end user, and country.

Based on cancer type, the South & Central America lung cancer screening market is segmented into non-small cell lung cancer (NSCLC), and small cell lung cancer. The non-small cell lung cancer (NSCLC) segment held a larger share of the South & Central America lung cancer screening market in 2022.

Based on technology, the South & Central America lung cancer screening market is segmented into chest X-ray, low dose computed tomography (LDCT), liquid biopsy, and others. Chest X-ray segment held the largest share of the South & Central America lung cancer screening market in 2022.

Based on age group, the South & Central America lung cancer screening market is segmented into 50 and older, and below 50. 50 and older segment held the larger share of the South & Central America lung cancer screening market in 2022.

Based on end user, the South & Central America lung cancer screening market is segmented into hospital, diagnostic centre, and others. Hospital segment held the largest share of the South & Central America lung cancer screening market in 2022.

Based on country, the South & Central America lung cancer screening market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America lung cancer screening market in 2022.

Siemens AG, Koninklijke Philips NV, Canon Inc, Medtronic, and GE HealthCare technologies Inc are some of the leading companies operating in the South & Central America lung cancer screening market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America Lung Cancer Screening Market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in South & Central America Lung Cancer Screening Market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth South & Central America Market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.